Margaret Thatcher was admitted to hospital last night for «routine tests»
as a result of a condition which kept her from Downing Street on her birthday party.
Not exact matches
Important factors that could cause actual
results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability
of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost
of accommodating, announced increases in the build rates
of certain aircraft; 6) the effect on aircraft demand and build rates
of changing customer preferences for business aircraft, including the effect
of global economic
conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals
as a
result of global economic uncertainty or otherwise; 8) the effect
of economic
conditions in the industries and markets in
which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution
of key milestones such
as the receipt
of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation
of our announced acquisition
of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability
of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk
of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production
of aircraft
resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts
of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak
of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact
of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition
of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect
of governmental laws, such
as U.S. export control laws and U.S. and foreign anti-bribery laws such
as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect
of changes in tax law, such
as the effect
of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations
of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect
of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers,
as well
as the cost and availability
of raw materials and purchased components; 23) our ability to recruit and retain a critical mass
of highly - skilled employees and our relationships with the unions representing many
of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment
of interest on, and principal
of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness
of any interest rate hedging programs; 28) the effectiveness
of our internal control over financial reporting; 29) the outcome or impact
of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition
of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco
as a
result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks
of doing business internationally, including fluctuations in foreign current exchange rates, impositions
of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.
Lithium - ion batteries become less capable
of supplying peak current demands when in cold
conditions, have a low battery charge or
as they age over time,
which can
result in the device unexpectedly shutting down to protect its electronic components.
Further, PDC urges you to carefully review and consider the cautionary statements and disclosures, specifically those under the heading «Risk Factors,» made in its Quarterly Report on Form 10 - Q, its Annual Report on Form 10 - K for the year ended December 31, 2016 (the «2016 Form 10 - K»), filed with the U.S. Securities and Exchange Commission («SEC») on February 28, 2017 and amended on May 1, 2018, and other filings with the SEC for further information on risks and uncertainties that could affect the Company's business, financial
condition,
results of operations, and prospects,
which are incorporated by this reference
as though fully set forth herein.
They often suffer from both mental and physical health problems at a higher rate than workers in other industries
as a
result of their working
conditions,
which include operating under hard - nosed management practices and getting yelled at all day by irate customers.
Actual
results and the timing
of events could differ materially from those anticipated in the forward - looking statements due to these risks and uncertainties
as well
as other factors,
which include, without limitation: the uncertain timing
of, and risks relating to, the executive search process; risks related to the potential failure
of eptinezumab to demonstrate safety and efficacy in clinical testing; Alder's ability to conduct clinical trials and studies
of eptinezumab sufficient to achieve a positive completion; the availability
of data at the expected times; the clinical, therapeutic and commercial value
of eptinezumab; risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture
of eptinezumab; Alder's ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights
of others; the uncertain timing and level
of expenses associated with Alder's development and commercialization activities; the sufficiency
of Alder's capital and other resources; market competition; changes in economic and business
conditions; and other factors discussed under the caption «Risk Factors» in Alder's Annual Report on Form 10 - K for the fiscal year ended December 31, 2017,
which was filed with the Securities and Exchange Commission (SEC) on February 26, 2018, and is available on the SEC's website at www.sec.gov.
Such risks, uncertainties and other factors include, without limitation: (1) the effect
of economic
conditions in the industries and markets in
which United Technologies and Rockwell Collins operate in the U.S. and globally and any changes therein, including financial market
conditions, fluctuations in commodity prices, interest rates and foreign currency exchange rates, levels
of end market demand in construction and in both the commercial and defense segments
of the aerospace industry, levels
of air travel, financial
condition of commercial airlines, the impact
of weather
conditions and natural disasters and the financial
condition of our customers and suppliers; (2) challenges in the development, production, delivery, support, performance and realization
of the anticipated benefits
of advanced technologies and new products and services; (3) the scope, nature, impact or timing
of acquisition and divestiture or restructuring activity, including the pending acquisition
of Rockwell Collins, including among other things integration
of acquired businesses into United Technologies» existing businesses and realization
of synergies and opportunities for growth and innovation; (4) future timing and levels
of indebtedness, including indebtedness expected to be incurred by United Technologies in connection with the pending Rockwell Collins acquisition, and capital spending and research and development spending, including in connection with the pending Rockwell Collins acquisition; (5) future availability
of credit and factors that may affect such availability, including credit market
conditions and our capital structure; (6) the timing and scope
of future repurchases
of United Technologies» common stock,
which may be suspended at any time due to various factors, including market
conditions and the level
of other investing activities and uses
of cash, including in connection with the proposed acquisition
of Rockwell; (7) delays and disruption in delivery
of materials and services from suppliers; (8) company and customer - directed cost reduction efforts and restructuring costs and savings and other consequences thereof; (9) new business and investment opportunities; (10) our ability to realize the intended benefits
of organizational changes; (11) the anticipated benefits
of diversification and balance
of operations across product lines, regions and industries; (12) the outcome
of legal proceedings, investigations and other contingencies; (13) pension plan assumptions and future contributions; (14) the impact
of the negotiation
of collective bargaining agreements and labor disputes; (15) the effect
of changes in political
conditions in the U.S. and other countries in
which United Technologies and Rockwell Collins operate, including the effect
of changes in U.S. trade policies or the U.K.'s pending withdrawal from the EU, on general market
conditions, global trade policies and currency exchange rates in the near term and beyond; (16) the effect
of changes in tax (including U.S. tax reform enacted on December 22, 2017,
which is commonly referred to
as the Tax Cuts and Jobs Act
of 2017), environmental, regulatory (including among other things import / export) and other laws and regulations in the U.S. and other countries in
which United Technologies and Rockwell Collins operate; (17) the ability
of United Technologies and Rockwell Collins to receive the required regulatory approvals (and the risk that such approvals may
result in the imposition
of conditions that could adversely affect the combined company or the expected benefits
of the merger) and to satisfy the other
conditions to the closing
of the pending acquisition on a timely basis or at all; (18) the occurrence
of events that may give rise to a right
of one or both
of United Technologies or Rockwell Collins to terminate the merger agreement, including in circumstances that might require Rockwell Collins to pay a termination fee
of $ 695 million to United Technologies or $ 50 million
of expense reimbursement; (19) negative effects
of the announcement or the completion
of the merger on the market price
of United Technologies» and / or Rockwell Collins» common stock and / or on their respective financial performance; (20) risks related to Rockwell Collins and United Technologies being restricted in their operation
of their businesses while the merger agreement is in effect; (21) risks relating to the value
of the United Technologies» shares to be issued in connection with the pending Rockwell acquisition, significant merger costs and / or unknown liabilities; (22) risks associated with third party contracts containing consent and / or other provisions that may be triggered by the Rockwell merger agreement; (23) risks associated with merger - related litigation or appraisal proceedings; and (24) the ability
of United Technologies and Rockwell Collins, or the combined company, to retain and hire key personnel.
Lithium - ion batteries become less capable
of supplying peak current demands when they are in cold
conditions, have a low battery charge, or
as they age over time,
which can
result in the device unexpectedly shutting down to protect its electronic components.
Actual
results, including with respect to our targets and prospects, could differ materially due to a number
of factors, including the risk that we may not obtain sufficient orders to achieve our targeted revenues; price competition in key markets; the risk that we or our channel partners are not able to develop and expand customer bases and accurately anticipate demand from end customers,
which can
result in increased inventory and reduced orders
as we experience wide fluctuations in supply and demand; the risk that our commercial Lighting Products
results will continue to suffer if new issues arise regarding issues related to product quality for this business; the risk that we may experience production difficulties that preclude us from shipping sufficient quantities to meet customer orders or that
result in higher production costs and lower margins; our ability to lower costs; the risk that our
results will suffer if we are unable to balance fluctuations in customer demand and capacity, including bringing on additional capacity on a timely basis to meet customer demand; the risk that longer manufacturing lead times may cause customers to fulfill their orders with a competitor's products instead; the risk that the economic and political uncertainty caused by the proposed tariffs by the United States on Chinese goods, and any corresponding Chinese tariffs in response, may negatively impact demand for our products; product mix; risks associated with the ramp - up
of production
of our new products, and our entry into new business channels different from those in
which we have historically operated; the risk that customers do not maintain their favorable perception
of our brand and products,
resulting in lower demand for our products; the risk that our products fail to perform or fail to meet customer requirements or expectations,
resulting in significant additional costs, including costs associated with warranty returns or the potential recall
of our products; ongoing uncertainty in global economic
conditions, infrastructure development or customer demand that could negatively affect product demand, collectability
of receivables and other related matters
as consumers and businesses may defer purchases or payments, or default on payments; risks
resulting from the concentration
of our business among few customers, including the risk that customers may reduce or cancel orders or fail to honor purchase commitments; the risk that we are not able to enter into acceptable contractual arrangements with the significant customers
of the acquired Infineon RF Power business or otherwise not fully realize anticipated benefits
of the transaction; the risk that retail customers may alter promotional pricing, increase promotion
of a competitor's products over our products or reduce their inventory levels, all
of which could negatively affect product demand; the risk that our investments may experience periods
of significant stock price volatility causing us to recognize fair value losses on our investment; the risk posed by managing an increasingly complex supply chain that has the ability to supply a sufficient quantity
of raw materials, subsystems and finished products with the required specifications and quality; the risk we may be required to record a significant charge to earnings if our goodwill or amortizable assets become impaired; risks relating to confidential information theft or misuse, including through cyber-attacks or cyber intrusion; our ability to complete development and commercialization
of products under development, such
as our pipeline
of Wolfspeed products, improved LED chips, LED components, and LED lighting products risks related to our multi-year warranty periods for LED lighting products; risks associated with acquisitions, divestitures, joint ventures or investments generally; the rapid development
of new technology and competing products that may impair demand or render our products obsolete; the potential lack
of customer acceptance for our products; risks associated with ongoing litigation; and other factors discussed in our filings with the Securities and Exchange Commission (SEC), including our report on Form 10 - K for the fiscal year ended June 25, 2017, and subsequent reports filed with the SEC.
For example, the expected timing and likelihood
of completion
of the proposed merger, including the timing, receipt and terms and
conditions of any required governmental and regulatory approvals
of the proposed merger that could reduce anticipated benefits or cause the parties to abandon the transaction, the ability to successfully integrate the businesses, the occurrence
of any event, change or other circumstances that could give rise to the termination
of the merger agreement, the possibility that Kraft shareholders may not approve the merger agreement, the risk that the parties may not be able to satisfy the
conditions to the proposed transaction in a timely manner or at all, risks related to disruption
of management time from ongoing business operations due to the proposed transaction, the risk that any announcements relating to the proposed transaction could have adverse effects on the market price
of Kraft's common stock, and the risk that the proposed transaction and its announcement could have an adverse effect on the ability
of Kraft and Heinz to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on their operating
results and businesses generally, problems may arise in successfully integrating the businesses
of the companies,
which may
result in the combined company not operating
as effectively and efficiently
as expected, the combined company may be unable to achieve cost - cutting synergies or it may take longer than expected to achieve those synergies, and other factors.
Given the absence
of a public trading market
of our common stock, and in accordance with the American Institute
of Certified Public Accountants Accounting and Valuation Guide, Valuation
of Privately - Held Company Equity Securities Issued
as Compensation, our board
of directors exercised reasonable judgment and considered numerous and subjective factors to determine the best estimate
of fair value
of our common stock, including independent third - party valuations
of our common stock; the prices at
which we sold shares
of our convertible preferred stock to outside investors in arms - length transactions; the rights, preferences, and privileges
of our convertible preferred stock relative to those
of our common stock; our operating
results, financial position, and capital resources; current business
conditions and projections; the lack
of marketability
of our common stock; the hiring
of key personnel and the experience
of our management; the introduction
of new products; our stage
of development and material risks related to our business; the fact that the option grants involve illiquid securities in a private company; the likelihood
of achieving a liquidity event, such
as an initial public offering or a sale
of our company given the prevailing market
conditions and the nature and history
of our business; industry trends and competitive environment; trends in consumer spending, including consumer confidence; and overall economic indicators, including gross domestic product, employment, inflation and interest rates, and the general economic outlook.
Actual
results may vary materially from those expressed or implied by forward - looking statements based on a number
of factors, including, without limitation: (1) risks related to the consummation
of the Merger, including the risks that (a) the Merger may not be consummated within the anticipated time period, or at all, (b) the parties may fail to obtain shareholder approval
of the Merger Agreement, (c) the parties may fail to secure the termination or expiration
of any waiting period applicable under the HSR Act, (d) other
conditions to the consummation
of the Merger under the Merger Agreement may not be satisfied, (e) all or part
of Arby's financing may not become available, and (f) the significant limitations on remedies contained in the Merger Agreement may limit or entirely prevent BWW from specifically enforcing Arby's obligations under the Merger Agreement or recovering damages for any breach by Arby's; (2) the effects that any termination
of the Merger Agreement may have on BWW or its business, including the risks that (a) BWW's stock price may decline significantly if the Merger is not completed, (b) the Merger Agreement may be terminated in circumstances requiring BWW to pay Arby's a termination fee
of $ 74 million, or (c) the circumstances
of the termination, including the possible imposition
of a 12 - month tail period during
which the termination fee could be payable upon certain subsequent transactions, may have a chilling effect on alternatives to the Merger; (3) the effects that the announcement or pendency
of the Merger may have on BWW and its business, including the risks that
as a
result (a) BWW's business, operating
results or stock price may suffer, (b) BWW's current plans and operations may be disrupted, (c) BWW's ability to retain or recruit key employees may be adversely affected, (d) BWW's business relationships (including, customers, franchisees and suppliers) may be adversely affected, or (e) BWW's management's or employees» attention may be diverted from other important matters; (4) the effect
of limitations that the Merger Agreement places on BWW's ability to operate its business, return capital to shareholders or engage in alternative transactions; (5) the nature, cost and outcome
of pending and future litigation and other legal proceedings, including any such proceedings related to the Merger and instituted against BWW and others; (6) the risk that the Merger and related transactions may involve unexpected costs, liabilities or delays; (7) other economic, business, competitive, legal, regulatory, and / or tax factors; and (8) other factors described under the heading «Risk Factors» in Part I, Item 1A
of BWW's Annual Report on Form 10 - K for the fiscal year ended December 25, 2016,
as updated or supplemented by subsequent reports that BWW has filed or files with the SEC.
We caution you that these statements are not guarantees
of future performance and are subject to numerous risks and uncertainties, including volatility in the economy and the credit markets, supply and demand changes for vacation ownership and residential products, competitive
conditions; the availability
of capital to finance growth, and other matters referred to under the heading «Risk Factors» contained in the Information Statement filed
as an exhibit to our Annual Report on Form 10 - K for the year ended December 30, 2011 filed with the U.S. Securities and Exchange Commission (the «SEC») and in subsequent SEC filings, any
of which could cause actual
results to differ materially from those expressed in or implied in this presentation.
In addition, terms and
conditions in the leveraged - loan market,
which provides credit to lower - rated companies, have eased significantly, reportedly
as a
result of a «reach for yield» in the face
of persistently low interest rates.
This volatility is likely to lead to a situation in
which companies with a high level
of risk meet the threshold
conditions for inclusion in indices solely
as a
result of exceptional trading, even before they have any business activity whose
results can be evaluated.»
Certainly, similar to secular society the Church, too, rests on certain presuppositions
which are not produced by the free decision
of her members and their free association
as such, but are the very
conditions of her existence, namely human nature, the saving will
of God, redemption through Jesus Christ, the general call
of all men to the Church and the
resulting «duty» to belong to her.
As a
result mind (or reason) ends up being placed in a purely contingent relation to some finite set
of naturalistic
conditions to
which it is fatalistically enslaved, thereby reducing the rational search for unity
of structure to simple naturalistic needs, desires, or drives.
Whatever happens, happens
as the
result of the creature's self - activity in utilizing its causal
conditions to achieve its ends, but God is everywhere and at all times seeking that
which is best, given the circumstances.
And so
of any other arrangement, bad or good,
which might
as a matter
of fact be found
resulting anywhere from previous
conditions.
As a
result, we are totally dependent upon God to initiate salvation for us,
which He did in eternity past by choosing to save some, without any
condition or merit on the part
of those whom He chose (Unconditional Election).
If you want the TRUEST
of the TRUE peri peri sauce experiences, you'll make this with African Bird's Eye peppers grown in Africa,
as the soil
conditions there are completely different than anywhere else in the world,
which influences the pepper flavor, and therefore the
resulting sauce.
As it was expedient for the player to play his next stroke with another club, which resulted in interference from the condition, he would have the option of playing the ball as it lies or proceeding again under Rule 25 - 1
As it was expedient for the player to play his next stroke with another club,
which resulted in interference from the
condition, he would have the option
of playing the ball
as it lies or proceeding again under Rule 25 - 1
as it lies or proceeding again under Rule 25 - 1b.
When the baby sleeps, they spend a lot
of time with the head in one position,
which can
result to a flat pressure spot on the back
of the head - a
condition referred to
as positional plagiocephaly.
Without urgent and ambitious government intervention, NEA estimates that in the next 15 years the cumulative effect will be 125,000 premature deaths
as a
result of living in cold homes; # 950m
of fuel debt
which will not be spent in local economies; and # 22 billion spent by the NHS in treating cold - related
conditions.
Osteoarthritis (OA, also known
as degenerative arthritis or degenerative joint disease, and sometimes referred to
as «arthrosis» or «osteoarthrosis»), is a
condition in
which low - grade inflammation
results in pain in the joints, caused by wearing
of the cartilage that covers and acts
as a cushion inside joints.
The
results suggest biomass burning
of polluted forest fuels may exacerbate poor air quality — and related health concerns — in some
of the world's most heavily polluted areas, among them, the Los Angeles metropolitan area,
which is expected to suffer from more wildfires
as drought
conditions continue.
In the U.S., one in every four deaths is a
result of heart disease,
which includes a range
of conditions from arrhythmias, or abnormal heart rhythms, to defects,
as well
as blood vessel diseases, more commonly known
as cardiovascular diseases.
About ten years ago, research
results showed that things are not quite
as simple
as that: «Under most
conditions, H2O2 is not an undesired side product but rather an essential chemical messenger that plays an important role in regulating the way in
which body cells respond to signals from outside such
as hormones and growth factors,» says Dr. Tobias Dick
of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ).
RoR dams can cause a spike in methylmercury in two ways — they can form small reservoirs, called headponds,
which flood soil and create slow - flowing, low - oxygen environments; or they can create higher temperatures in the stream
as a
result of the reduced flow
conditions when portions
of the stream are diverted to the turbines.
As part
of these ongoing research activities, the DNA
of Dravet patients without SCN1A mutations was analyzed by trio exome sequencing,
which searches across the active parts
of the genome for de novo mutations that have arisen in these patients (de novo mutations are DNA copying errors that occur in the parents» gametes or in the fertilized egg or embryo,
resulting in the afflicted family member being the first person in their family to have this genetic
condition).
Prof. Schuelke emphasizes: «Our
results are a good example
of how the study
of rare genetic diseases can provide insights into general disease mechanisms,
which may also play a role in other
conditions, such
as paraplegia, and
which may give rise to the development
of regenerative therapies.»
Published October 29, 2015 in the journal Science, the new
results lend insights into potential mechanisms
of chronic itch,
which is caused by a variety
of conditions such
as eczema, diabetic neuropathy, multiple sclerosis and certain types
of cancers.
They add: «What is similar between now and then is the human genetic material, our genome, including ancient polymorphisms that were uncovered to predispose the carrier to the development
of atherosclerotic cardiovascular disease... however, our ancient ancestors were certainly susceptible to many other
conditions, such
as infectious diseases, nutritional deprivation, and trauma,
which often
resulted in death at an early age, before atherosclerotic heart disease had a clinical impact.»
«These
results are important for understanding the onset
of illness in
conditions such
as schizophrenia, depression or ADHD,
which mostly occur at the threshold
of adulthood.
«In the majority
of patients, bariatric surgery may
result in the remission
of many cardiovascular disease risk factors,
which could prevent those patients from experiencing more serious health
conditions, such
as heart attack and stroke,» Coleman said.
The preservation
of ideally both kidneys is important because the kidney performs a range
of vital functions
which diminish with age and
as a
result of kidney - damaging
conditions such
as diabetes and high blood pressure.
Influenza remains a major health problem in the United States,
resulting each year in an estimated 36,000 deaths and 200,000 hospitalizations.4 Those who have been shown to be at high risk for the complications
of influenza infection are children 6 to 23 months
of age; healthy persons 65 years
of age or older; adults and children with chronic diseases, including asthma, heart and lung disease, and diabetes; residents
of nursing homes and other long - term care facilities; and pregnant women.4 It is for this reason that the Centers for Disease Control and Prevention (CDC) has recommended that these groups, together with health care workers and others with direct patient - care responsibilities, should be given priority for influenza vaccination this season in the face
of the current shortage.1 Other high - priority groups include children and teenagers 6 months to 18 years
of age whose underlying medical
condition requires the daily use
of aspirin and household members and out -
of - home caregivers
of infants less than 6 months old.1 Hence, in the case
of vaccine shortages
resulting either from the unanticipated loss
of expected supplies or from the emergence
of greater - than - expected global influenza activity — such
as pandemic influenza,
which would prompt a greater demand for vaccination5 — the capability
of extending existing vaccine supplies by using alternative routes
of vaccination that would require smaller doses could have important public health implications.
These
resulted in significant contributions to our understanding
of the solution
conditions that determine polypeptide conformation and to the development
of techniques, particularly optical rotatory dispersion, for determining the - helical and β - sheet contents
of various key proteins (4)(most notably myoglobin, the helical content
of which was confirmed by John Kendrew's X-ray structure analysis)
as well
as the helical nature
of the three - stranded protein collagen.
Dr Brooks will be presenting the
results of a single - center, randomized, double - blind, placebo - controlled clnical trial
which was conducted to evaluate the safety, tolerability and clinical endpoint responsiveness
of a drug called Ibudilast (or MN - 166) in subjects with the neurodegenerative
condition, Amyotrophic Lateral Sclerosis (or ALS — also known
as motor neuron disease; Click here to read a previous SoPD post about ALS and Click here to learn more about this clinical trial).
Integrated systems biology approaches can identify gene regulatory networks, such
as immune, stress and other regulatory responses, and link them with physiologic states.6 This bioinformatics approach provides an unbiased view
of the immune system profile, and can be linked to changes in environmental
conditions.7 These network approaches, while often applied to identifying disease profiles, can be used to identify salutary states
as well, such
as that
which might
result from intensive meditation.
indirect effect A secondary impact to a system from a change that was caused by shifting climate
conditions, such
as increased fire frequency,
which is a
result of drier
conditions caused by an increase in temperature.
Gordon Brown, whose youngest son suffers from cystic fibrosis, one
of the
conditions which scientists hope may be treated
as a
result of the research, launched a passionate defence
of the Bill, on
which Labour MPs have a free vote.
The transition from closed to open state often leads to extensive physical and chemical changes in the estuarine
conditions,
as water mixing and sediment resuspension are increased,
which could
result in the oxidation
of sediment acid - volatile sulfides (AVS).
Some aspects
of mammalian aging
result from an age - associated functional decline
of adult stem cells, the type
of cells
which act
as a repair system for our bodies and replenish adult tissues, particularly under stress or aging
conditions.
The
condition comes about when the lining that typically is on the inside
of the uterus begins growing on other part
of the reproductive system (such
as fallopian tubes and ovaries) thus destroying or weakening them,
which can
result in infertility.
This study demonstrates that incorporating a mind - body exercise such
as tai chi
which is readily available in the community could improve the
results of depression treatment in older individuals, who might also have additional co-existing
conditions, or cognitive impairment.
Even though some studies have produced evidence that putting the muscle under extreme
conditions might
result in slight increases in the number
of fibers, a process known
as hyperplasia, the mechanism
which is responsible for increasing muscle size is called hypertrophy,
which is the increase in the size
of the already existing muscle fibers.
One theory proposes that once the storage capacity
of subcutaneous adipose tissue (SAT) depots is exceeded under
conditions of energy excess, either
as a
result of impaired expandability and / or excessive hypertrophic growth, fat deposition within visceral depots and non-adipose tissues including the liver, skeletal muscle and pancreas can ensue.93 This can subsequently lead to the development
of systemic IR and a series
of associated cardiometabolic disorders including dyslipidaemia, dysglycaemia, hyperinsulinaemia and hypertension.3 Expression
of pro-inflammatory mediators including interleukins 1 (IL - 1), 6 (IL - 6), tumour necrosis factor alpha (TNF - α) and resistin, are also increased
which can further potentiate IR and promote atherosclerosis.
Thus, if any inflammation is present,
which is found in numerous clinical and subclinical
conditions (
as above), the body will have lower cellular T3 levels that are often inadequate for optimal functioning; but the pituitary will have increased levels
of T3,
resulting in a lowering
of the TSH that would potentially be inappropriately interpreted
as an indication
of «normal» thyroid levels.
In the treatment
of an overactive thyroid,
which most commonly
results from the autoimmune
condition known
as Graves» disease, it is critical to slow down the gland's excess production
of thyroid hormones, especially the hormones thyroxine (T4) and triiodothyronine (T3).